CY1119907T1 - Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου - Google Patents

Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου

Info

Publication number
CY1119907T1
CY1119907T1 CY20181100159T CY181100159T CY1119907T1 CY 1119907 T1 CY1119907 T1 CY 1119907T1 CY 20181100159 T CY20181100159 T CY 20181100159T CY 181100159 T CY181100159 T CY 181100159T CY 1119907 T1 CY1119907 T1 CY 1119907T1
Authority
CY
Cyprus
Prior art keywords
treatment
chromon
production
component
autism spectrum
Prior art date
Application number
CY20181100159T
Other languages
English (en)
Inventor
Agnès AUCLAIR
Paul Moser
Pierre Sokoloff
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of CY1119907T1 publication Critical patent/CY1119907T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αξιώνει ένα παράγωγο χρωμόνης και φαρμακευτικές συνθέσεις και συνδυασμούς οι οποίοι περιλαμβάνουν τουλάχιστον το εν λόγω παράγωγο, το οποίο είναι ένας ανταγωνιστής του D3 υποδοχέα ντοπαμίνης, για τη χρήση τους για την αντιμετώπιση διαταραχής του φάσματος του αυτισμού.
CY20181100159T 2013-12-13 2018-02-09 Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου CY1119907T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306726 2013-12-13
EP14812465.4A EP3079688B1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder
PCT/EP2014/077635 WO2015086836A1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder

Publications (1)

Publication Number Publication Date
CY1119907T1 true CY1119907T1 (el) 2018-06-27

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100159T CY1119907T1 (el) 2013-12-13 2018-02-09 Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου

Country Status (30)

Country Link
US (1) US10028948B2 (el)
EP (1) EP3079688B1 (el)
JP (1) JP6419826B2 (el)
KR (1) KR102280530B1 (el)
CN (1) CN105792824B (el)
AU (1) AU2014363428B2 (el)
BR (1) BR112016012552A8 (el)
CA (1) CA2932791C (el)
CY (1) CY1119907T1 (el)
DK (1) DK3079688T3 (el)
ES (1) ES2657706T3 (el)
HK (1) HK1223563A1 (el)
HR (1) HRP20180323T8 (el)
HU (1) HUE036035T2 (el)
IL (1) IL245996B (el)
LT (1) LT3079688T (el)
MA (1) MA39076A1 (el)
MX (1) MX2016007612A (el)
MY (1) MY172937A (el)
NO (1) NO3079688T3 (el)
NZ (1) NZ720868A (el)
PL (1) PL3079688T3 (el)
PT (1) PT3079688T (el)
RS (1) RS56931B1 (el)
RU (2) RU2019104946A (el)
SA (1) SA516371298B1 (el)
SI (1) SI3079688T1 (el)
TN (1) TN2016000213A1 (el)
UA (1) UA117271C2 (el)
WO (1) WO2015086836A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY156288A (en) 2008-07-16 2016-01-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) * 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
US6605607B1 (en) * 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
EP1793671B1 (en) * 2004-09-20 2011-04-27 Mount Sinai School of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
US20110294879A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
KR101921772B1 (ko) * 2011-05-13 2018-11-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
FR2976179A1 (fr) * 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
EP3079688A1 (en) 2016-10-19
US20160303117A1 (en) 2016-10-20
KR20160088886A (ko) 2016-07-26
BR112016012552A8 (pt) 2022-11-08
HRP20180323T1 (hr) 2018-04-06
DK3079688T3 (da) 2018-01-29
LT3079688T (lt) 2018-02-12
ES2657706T3 (es) 2018-03-06
RS56931B1 (sr) 2018-05-31
HRP20180323T8 (hr) 2019-01-25
MA39076A1 (fr) 2017-05-31
SI3079688T1 (en) 2018-03-30
IL245996B (en) 2018-11-29
RU2019104946A (ru) 2019-04-01
CN105792824B (zh) 2018-08-03
AU2014363428B2 (en) 2019-09-12
MX2016007612A (es) 2016-09-09
RU2686110C1 (ru) 2019-04-24
HUE036035T2 (hu) 2018-06-28
JP6419826B2 (ja) 2018-11-07
PL3079688T3 (pl) 2018-05-30
IL245996A0 (en) 2016-07-31
US10028948B2 (en) 2018-07-24
HK1223563A1 (zh) 2017-08-04
UA117271C2 (uk) 2018-07-10
EP3079688B1 (en) 2017-11-22
AU2014363428A1 (en) 2016-06-23
PT3079688T (pt) 2018-02-28
CA2932791A1 (en) 2015-06-18
WO2015086836A1 (en) 2015-06-18
MY172937A (en) 2019-12-16
SA516371298B1 (ar) 2018-06-07
NO3079688T3 (el) 2018-04-21
TN2016000213A1 (en) 2017-10-06
CA2932791C (en) 2021-11-09
NZ720868A (en) 2022-04-29
CN105792824A (zh) 2016-07-20
KR102280530B1 (ko) 2021-07-21
JP2016540000A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
CY1119907T1 (el) Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CR20160419A (es) Nuevos compuestos biciclicos
DK3313838T3 (da) Polycykliske amidderivater som cdk9-inhibitorer
DK3104718T3 (da) Tobaksholdig gelsammensætning
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
DK3634468T3 (da) Fast sammensætning til oral indgivelse
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112017002508A2 (pt) novos compostos substituídos com halogênio
DK3371168T3 (da) Indolin-2-on-derivater
BR112016018371A2 (pt) derivado de indolona substituído com pirrol, método de preparação do mesmo, composição compreendendo o mesmo e uso do mesmo
CL2019001038A1 (es) Composición para el cuidado bucal.
DK3389633T3 (da) Farmaceutiske sammensætninger, der omfatter phenylaminopyrimidinderivat
BR112017002509A2 (pt) novos compostos substituídos com halogênio
CL2019001624A1 (es) Composición para el cuidado bucal.
CL2019000323A1 (es) Composición para el cuidado bucal.
KR20180084728A (ko) 구강용 조성물
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid